Cardiac computed tomography imaging in familial hypercholesterolaemia: Implications for therapy and clinical trials

Current Opinion in Lipidology

Volumn 26, Issue 6, 2015, Pages 586-592

  Sijbrands, Eric J G ^a   Nieman, Koen ^a   Budoff, Matthew J ^b   Harada Shiba, Mariko ^c   Ogura, Masatsune ^c   Nohara, Atsushi ^d   Sullivan, David R ^e   Watts, Gerald F ^f,g   Bell, Damon A ^f,g   Karlezi, Rodrigo Alonso ^h   Miname, Marcio H ⁱ   Gidding, Sam S ^j,k   Stefanutti, Claudia ^l   Mata, Pedro ^m   Bruckert, Eric ⁿ   Wierzbicki, Anthony S ^o   Defesche, Joep C ^p   Wiegman, Bert ^p   Monique, Mulder ^a   Van Lennep, Jeanine Roeters ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h CLÍNICA LAS CONDES   (Chile)

ⁱ UNIVERSITY OF SÃO PAULO   (Brazil)

^j NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l POLICLINICO UMBERTO I   (Italy)

^m Medicina Interna   (Spain)

ⁿ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^o GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^p ACADEMIC MEDICAL CENTER   (Netherlands)

more..

Author keywords

cholesterol lowering; computed tomographic angiography; coronary atherosclerosis; familial hypercholesterolemia; surrogate endpoint

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANGIOCARDIOGRAPHY; ATHEROSCLEROTIC PLAQUE; CARDIAC IMAGING; CARDIOVASCULAR MORTALITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK PATIENT; HUMAN; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLINICAL TRIAL (TOPIC); COMPLICATION; CORONARY ANGIOGRAPHY; DIAGNOSTIC IMAGING; HYPERLIPOPROTEINEMIA TYPE II; PROCEDURES; X-RAY COMPUTED TOMOGRAPHY;

CLINICAL TRIALS AS TOPIC; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84957676364     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000249     Document Type: Review

References (42)

1. van Waardhuizen CN, Langhout M, Ly F, et al. Diagnostic performance and comparative cost-effectiveness of noninvasive imaging tests in patients presenting with chronic stable chest pain with suspected coronary artery disease: a systematic overview. Curr Cardiol Rep 2014; 16:537.
2. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171:309-325.
3. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337:a2423.
4. Neefjes LA, Ten Kate GJ, Rossi A, et al. CT coronary plaque burden in asymptomatic patients with familial hypercholesterolaemia. Heart 2011; 97:1151-1157.
5. Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 2011; 219:721-727.
6. Ten Kate GJ, Neefjes LA, Dedic A, et al. The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2013; 227:334-341.
7. Caballero P, Alonso R, Rosado P, et al. Detection of subclinical atherosclerosis in familial hypercholesterolemia using noninvasive imaging modalities. Atherosclerosis 2012; 222:468-472.
8. Miname MH, Ribeiro MS 2nd, Parga Filho J, et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 2010; 213:486-491.
9. Viladés Medel D, Leta Petracca R, Carreras Costa F, et al. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations. Am J Cardiol 2013; 111:955-961.
10. Tada H, Kawashiri M-A, Okada H, et al. Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography. Am J Cardiol 2015; 115:724-729.
11. Ten Kate GL, Ten Kate GJ, Van den Oord SC, et al. Carotid plaque burden as a measure of subclinical coronary artery disease in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2013; 111:1305-1310.
12. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010; 122:e584-e636.
13. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010; 303:1610-1616.
14. Raggi P, Shaw LJ, Berman DS, Callister TQ. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004; 43:1663-1669.
15. Shaw LJ, Raggi P, Callister TQ, Berman DS. Prognostic value of coronary artery calcium screening in asymptomatic smokers and nonsmokers. Eur Heart J 2006; 27:968-975.
16. Ratchford EV, Carson KA, Jones SR, Ashen MD. Usefulness of coronary and carotid imaging rather than traditional atherosclerotic risk factors to identify firefighters at increased risk for cardiovascular disease. Am J Cardiol 2014; 113:1499-1504.
17. Madaj PM, Budoff MJ, Li D, et al. Identification of noncalcified plaque in young persons with diabetes: an opportunity for early primary prevention of coronary artery disease identified with low-dose coronary computed tomographic angiography. Acad Radiol 2012; 19:889-893.
18. Maffei E, Seitun S, Nieman K, et al. Assessment of coronary artery disease and calcified coronary plaque burden by computed tomography in patients with and without diabetes mellitus. Eur Radiol 2011; 21:944-953.
19. Shaw LJ, Giambrone AE, Blaha MJ, et al. Long-term prognosis after coronary artery calcification testing in asymptomatic patients: a cohort study. Ann Intern Med 2015; 163:14-21.
20. Chow BJ, Small G, Yam Y, et al. Prognostic and therapeutic implications of statin and aspirin therapy in individuals with nonobstructive coronary artery disease: results from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter registry) registry. Arterioscler Thromb Vasc Biol 2015; 35:981-989.
21. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging 2009; 2:675-688.
22. Valenti V, O'Hartaigh B, Heo R, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9715 individuals. JACC Cardiovasc Imaging 2015; 8:900-909.
23. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994; 14:1066-1074.
24. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102:1438-1443.
25. Santos RD, Miname MH, Martinez LR, et al. Noninvasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multidetector row computed tomography angiography. Atherosclerosis 2008; 197:910-915.
26. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in The Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560-565.
27. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
28. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146-2157.
29. Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001; 322:1019-1023.
30. Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr 2014; 8:342-358.
31. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 2015; 65:1273-1282.
32. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29:2625-2633.
33. Hoffmann U, Dirisamer A, Heher S, et al. Relation of peripheral flowmediated vasodilatation and coronary arterial calcium in young patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2002; 90:70-73.
34. Gidding SS, Bookstein LC, Chomka EV. Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia. Circulation 1998; 98:2580-2583.
35. Mols RE, Jensen JM, Sand NP, et al. Visualization of coronary artery calcification: influence on risk modification. Am J Med 2015; 128:1023; e23-31.
36. Schlosser T, Mohrs OK, Magedanz A, et al. Noninvasive coronary angiography using 64-detector-row computed tomography in patients with a low to moderate pretest probability of significant coronary artery disease. Acta Radiol 2007; 48:300-307.
37. Young LH, Wackers FJ, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009; 301:1547-1555.
38. Muhlestein JB, Lappé DL, Lima JA, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014; 312:2234-2243.
39. Rinehart S, Vazquez G, Qian Z, et al. Quantitative measurements of coronary arterial stenosis, plaque geometry, and composition are highly reproducible with a standardized coronary arterial computed tomographic approach in high-quality CT datasets. J Cardiovasc Comput Tomogr 2011; 5:35-43.
40. Schuhbaeck A, Dey D, Otaki Y, et al. Interscan reproducibility of quantitative coronary plaque volume and composition from CT coronary angiography using an automated method. Eur Radiol 2014; 24:2300-2308.
41. Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression: a serial coronary CT angiography study. Atherosclerosis 2013; 231:198-204.
42. Nieman K, Serruys PW, Onuma Y, et al. Multislice computed tomography angiography for noninvasive assessment of the 18-month performance of a novel radiolucent bioresorbable vascular scaffolding device: the ABSORB trial (a clinical evaluation of the bioabsorbable everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). J Am Coll Cardiol 2013; 62:1813-1814.